Taking Longer Than Expected: QRxPharma’s MoxDuo Gets “Complete Response” As Firm Works On Data
This article was originally published in The Pink Sheet Daily
QRxPharma needs more time to complete a quality control report validating 30 million data points related to the marketing application for combination opioid analgesic MoxDuo. Faced with perplexed investors, CEO explains that a delay related to submitting the report is behind the latest “complete response” letter from FDA.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.